Trending...
- Items signed by Ayn Rand, Vladimir Lenin, MLK, JFK, Francis Crick, many others are in University Archives' June 17 online-only auction
- Paul Baldassini: In Full Bloom Art Exhibit at the Geary Gallery, Darien, CT
- Munger Construction and IBS Earn Four Honors in 2026 Varco Pruden Hall of Fame Awards
40 Year Quality Expert & Boeing Shareholder, Daryl Guberman Warned Major Manufacturers—including Medtronic, Boston Scientific, Smith & Nephew, and Johnson & Johnson—before The FDA Recall. The GUBERMAN Anomaly-Discovery, Now Exposes The Largest Multi Sector Oversight Failure In Modern U.S. History.
STRATFORD, Conn. - Hartok -- (The FDA's newly announced Class I recall of Boston Scientific implantable cardiac devices—citing 4 deaths and 2,557 serious injuries—has validated the early warnings issued by Daryl Guberman, CEO of Guberman PMC LLC, a 40‑year aerospace and medical‑materials quality expert.
On April 27, 2026, Guberman formally notified multiple manufacturers, including Medtronic, Boston Scientific, Smith & Nephew, Johnson & Johnson, Zimmer Biomet, and Stryker, that implantable devices manufactured under the compromised 2018–Present accreditation environment were at risk.
"This recall is not an isolated event," Guberman said. "It is the direct result of a systemic accreditation collapse that has contaminated medical devices, aerospace components, pharmaceuticals, and industrial materials."
FDA Recall Confirms the Warning
The FDA's Class I recall requires urgent in‑person software updates for thousands of implanted devices. The agency confirmed:
Multi‑Year Failure Pattern: ACCOLADE Pacemakers Have Been Failing for Years, Not Just 2026
The 2026 Class I recall is not the first failure involving Boston Scientific's ACCOLADE pacemaker line.
FDA records show a three‑year sequence of escalating failures, each involving different root causes — a clear sign of systemic manufacturing and oversight breakdown, not isolated defects.
FDA WARNINGS TO BOSTON SCIENTIFIC: 2-Years ACCOLADE Pacemakers
2024 —FDA SAFETY COMMUNICATION
Date Issued: December 16, 2024
Title: Accolade Pacemaker Devices by Boston Scientific and Potential Need for Early Device Replacement – FDA Safety Communication
Link:
https://www.fda.gov/medical-devices/safety-communications/accolade-pacemaker-devices-boston-scientific-and-potential-need-early-device-replacement-fda-safety
2025 — FDA CLASS I RECALL
Date Initiated by Firm: August 20, 2025
Title: Class I Device Recall – ACCOLADE Pacemakers
Link:
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRES/res.cfm?id=97467
2026 — FDA CLASS I RECALL / CORRECTION
More on hartok.com
Date Issued: May 2026
Title: Pacemaker Correction: Boston Scientific Issues Correction for ACCOLADE Pacemakers and CRT‑Ps
Link:
https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/pacemaker-correction-boston-scientific-issues-correction-accolade-pacemakers-and-crt-ps
This three‑year pattern proves that ACCOLADE failures are not new, not isolated, and not unpredictable — they are the direct result of the 2018–Present accreditation collapse that compromised ISO 13485 oversight across the medical‑device sector.
"The FDA recall confirms what I warned manufacturers about on April 27," Guberman said. "These failures were the inevitable outcome of a broken accreditation system."
Accreditation Breakdown: 2018–Present
Guberman's forensic reports document a collapse inside the ANSI‑ANAB accreditation structure beginning in 2018. This breakdown affected:
Cross‑Sector Impact: Medical, Aerospace, Industrial, and Pharmaceutical
The accreditation collapse is not limited to medical devices.
It affects:
WORLDWIDE FAILURE! :
"Whether it's a pacemaker or a jet engine, the same broken accreditation structure governs both," Guberman emphasized.
The GUBERMAN Anomaly: Largest Industrial Oversight Failure in U.S. History
The GUBERMAN Anomaly, first documented in 2018, has now expanded into what experts describe as the largest industrial, regulatory, and fiduciary oversight failure in modern U.S. history. https://guberman-quality.com/wp-content/uploads/2026/03/GUBERMAN-ANOMALY-FEBRUARY-2026.docx.pdf
Its reach includes:
More on hartok.com
"These agencies and investors understand the implications," Guberman said. "Their silence is not dismissal — it is fear."
Manufacturers Were Warned Before FDA Action
Guberman's April 27 advisory warned that devices manufactured between 2018 and 2026 may contain systemic vulnerabilities due to:
Public‑Health and Legal Exposure
The recall requires in‑person updates, meaning:
WARNING: Combined Medical Device ADVISORY And FDA Regulatory Framework Analysis https://www.prlog.org/13140353-warning-combined-medical-device-advisory-and-fda-regulatory-framework-analysis.html
Guberman warns that this event may trigger:
Hospitals are not storing these ACCOLADE pacemakers in temperature‑controlled environments. Most are placed in ordinary storage rooms, not climate‑regulated facilities. That means the integrity of the lithium‑based batteries can degrade while in custody — a risk the FDA, insurers, and manufacturers have completely ignored.
Lithium‑iodine and lithium‑silver‑vanadium batteries are engineered for stable, body‑temperature environments, not fluctuating heat, humidity, or cold. Improper storage accelerates:
And the failure goes deeper:
Hospitals are only required to keep explanted (taken out of the body) pacemakers for a short, preset period — typically 30 days, 60 days, or at most 90 days — because no federal regulation requires long‑term storage. Once that retention window expires, the hospital can legally dispose of the device, even if it may contain evidence of battery defects, seal failures, electrical instability, or manufacturing errors. This means critical proof is often destroyed before patients, families, investigators, or regulators ever have the chance to examine it. In a system already weakened by recalls and accreditation failures, these short expiration limits ensure that the most important evidence disappears.
All documents available at: https://guberman-quality.com
On April 27, 2026, Guberman formally notified multiple manufacturers, including Medtronic, Boston Scientific, Smith & Nephew, Johnson & Johnson, Zimmer Biomet, and Stryker, that implantable devices manufactured under the compromised 2018–Present accreditation environment were at risk.
"This recall is not an isolated event," Guberman said. "It is the direct result of a systemic accreditation collapse that has contaminated medical devices, aerospace components, pharmaceuticals, and industrial materials."
FDA Recall Confirms the Warning
The FDA's Class I recall requires urgent in‑person software updates for thousands of implanted devices. The agency confirmed:
- 4 patient deaths
- 2,557 serious injuries
- Life‑critical devices requiring immediate correction
Multi‑Year Failure Pattern: ACCOLADE Pacemakers Have Been Failing for Years, Not Just 2026
The 2026 Class I recall is not the first failure involving Boston Scientific's ACCOLADE pacemaker line.
FDA records show a three‑year sequence of escalating failures, each involving different root causes — a clear sign of systemic manufacturing and oversight breakdown, not isolated defects.
FDA WARNINGS TO BOSTON SCIENTIFIC: 2-Years ACCOLADE Pacemakers
2024 —FDA SAFETY COMMUNICATION
Date Issued: December 16, 2024
Title: Accolade Pacemaker Devices by Boston Scientific and Potential Need for Early Device Replacement – FDA Safety Communication
Link:
https://www.fda.gov/medical-devices/safety-communications/accolade-pacemaker-devices-boston-scientific-and-potential-need-early-device-replacement-fda-safety
2025 — FDA CLASS I RECALL
Date Initiated by Firm: August 20, 2025
Title: Class I Device Recall – ACCOLADE Pacemakers
Link:
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRES/res.cfm?id=97467
2026 — FDA CLASS I RECALL / CORRECTION
More on hartok.com
- The Lighting Quotient Announces tambient® ona™ at Fulton Market Design Days 2026
- About Fashion Sourcing: The Global Platform For All Your Apparel Clothing & Accessories Sourcing
- Haven Rock Solutions: Work Raptor™ Patent-Pending Camo System
- ACES Gallery's Spring Estates Auction on June 14th will feature 425 quality lots from prominent estates and collections
- Plootus Report: US Renters Face Persistent Cost Burden as National Average Rent Holds 30% Above Pre
Date Issued: May 2026
Title: Pacemaker Correction: Boston Scientific Issues Correction for ACCOLADE Pacemakers and CRT‑Ps
Link:
https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/pacemaker-correction-boston-scientific-issues-correction-accolade-pacemakers-and-crt-ps
This three‑year pattern proves that ACCOLADE failures are not new, not isolated, and not unpredictable — they are the direct result of the 2018–Present accreditation collapse that compromised ISO 13485 oversight across the medical‑device sector.
"The FDA recall confirms what I warned manufacturers about on April 27," Guberman said. "These failures were the inevitable outcome of a broken accreditation system."
Accreditation Breakdown: 2018–Present
Guberman's forensic reports document a collapse inside the ANSI‑ANAB accreditation structure beginning in 2018. This breakdown affected:
- Mill Test Reports
- Raw‑material certifications
- Subcontractor audits
- Chain‑of‑custody documentation
- Metallurgical verification for titanium, cobalt‑chrome, and implant alloys
Cross‑Sector Impact: Medical, Aerospace, Industrial, and Pharmaceutical
The accreditation collapse is not limited to medical devices.
It affects:
WORLDWIDE FAILURE! :
- Aerospace manufacturing (including Boeing's 24‑year AS9100 gap)
- Industrial and metallurgical supply chains
- Pharmaceutical production and packaging
- Defense and critical infrastructure components
"Whether it's a pacemaker or a jet engine, the same broken accreditation structure governs both," Guberman emphasized.
The GUBERMAN Anomaly: Largest Industrial Oversight Failure in U.S. History
The GUBERMAN Anomaly, first documented in 2018, has now expanded into what experts describe as the largest industrial, regulatory, and fiduciary oversight failure in modern U.S. history. https://guberman-quality.com/wp-content/uploads/2026/03/GUBERMAN-ANOMALY-FEBRUARY-2026.docx.pdf
Its reach includes:
- Medical implants
- Pharmaceuticals
- Aerospace systems
- Industrial manufacturing
- Defense supply chains
- Department of Homeland Security
- Department of Defense
- Department of Commerce
- NASA OIG
- House Committee on Science, Space & Technology
- FDA and FAA
More on hartok.com
- Justin Calabrese Reveals How He Balances Business, Fitness, Success, and Doctoral Life
- Entrepreneur and Author Justin Calabrese Reflects on Happiness, Leadership, and Memorial Day Travel
- "Songs of Slavery and Emancipation" Tour Comes to John Brown's Hometown
- CAL Business Solutions Receives Cavallo Top Contributor Award for Second Consecutive Year
- Emerald Lake Books Releases Why Not God?, Inviting Readers to Examine Faith, Truth and Meaning
"These agencies and investors understand the implications," Guberman said. "Their silence is not dismissal — it is fear."
Manufacturers Were Warned Before FDA Action
Guberman's April 27 advisory warned that devices manufactured between 2018 and 2026 may contain systemic vulnerabilities due to:
- Compromised accreditation
- Invalid certification pathways
- Faulty metallurgical documentation
- Audit failures
- Supplier oversight breakdowns
Public‑Health and Legal Exposure
The recall requires in‑person updates, meaning:
- Not all patients will receive the correction
- Some may not be aware of the recall
- Risk remains active until every device is updated
WARNING: Combined Medical Device ADVISORY And FDA Regulatory Framework Analysis https://www.prlog.org/13140353-warning-combined-medical-device-advisory-and-fda-regulatory-framework-analysis.html
Guberman warns that this event may trigger:
- Expanded recalls
- Congressional inquiries
- Legal action
- Re‑evaluation of FDA's reliance on ANSI‑ANAB
Hospitals are not storing these ACCOLADE pacemakers in temperature‑controlled environments. Most are placed in ordinary storage rooms, not climate‑regulated facilities. That means the integrity of the lithium‑based batteries can degrade while in custody — a risk the FDA, insurers, and manufacturers have completely ignored.
Lithium‑iodine and lithium‑silver‑vanadium batteries are engineered for stable, body‑temperature environments, not fluctuating heat, humidity, or cold. Improper storage accelerates:
- Battery degradation
- Internal pressure changes
- Seal stress
- Electrolyte instability
And the failure goes deeper:
Hospitals are only required to keep explanted (taken out of the body) pacemakers for a short, preset period — typically 30 days, 60 days, or at most 90 days — because no federal regulation requires long‑term storage. Once that retention window expires, the hospital can legally dispose of the device, even if it may contain evidence of battery defects, seal failures, electrical instability, or manufacturing errors. This means critical proof is often destroyed before patients, families, investigators, or regulators ever have the chance to examine it. In a system already weakened by recalls and accreditation failures, these short expiration limits ensure that the most important evidence disappears.
All documents available at: https://guberman-quality.com
Source: GUBERMAN-PMC,LLC
Filed Under: Aerospace, Daryl Guberman
0 Comments